Nashville, Tenn.-based Vanderbilt-Ingram Cancer Center joined forces with Tempus to inform cancer treatment decisions, the health technology company confirmed Jan. 4.
Tempus, a company focused on personalized oncology care, collects and analyzes large-scale databases of molecular and clinical information to support physicians treating cancer patients.
Under the agreement, Tempus will use its Tempus O platform to structure patient data from Vanderbilt-Ingram Cancer Center's EHR. The company will also provide the cancer center with next generation sequencing and analysis services to identify actionable gene alterations.
"Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient's cancer and its genetic and molecular drivers, with a goal of improving patient outcomes," said Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center.